PCM
PTGX icon

Prelude Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Prelude Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,012
Closed -$212K – 1471
2026
Q1 		$212K Buy
+2,012
New +$178K 0.02% 882
2020
Q1 		– Sell
-1,600
Closed -$11K – 1916
2019
Q4 		$11K Buy
+1,600
New +$15.9K ﹤0.01% 1690
2018
Q4 		– Sell
-683
Closed -$7K – 2092
2018
Q3 		$7K Sell
683
-4,517
-87% -$38.9K ﹤0.01% 1593
2018
Q2 		$35K Sell
5,200
-2,900
-36% -$22.3K ﹤0.01% 1229
2018
Q1 		$70K Buy
+8,100
New +$153K 0.01% 970

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Prelude Capital Management's PTGX Position: Q2 2026 in Review

Prelude Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 2,012 shares — an estimated $212K sold.

Prelude Capital Management first reported a position in PTGX in Q1 2018 and held it in 5 quarters. The position peaked at $212K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Prelude Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 2,012 Protagonist Therapeutics shares in Q2 2026, an estimated $212K.
  • Prelude Capital Management first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 5 quarters.
  • Prelude Capital Management's Protagonist Therapeutics position peaked at $212K in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.